Feb 2 (Reuters) - Regeneron beat Wall Street estimates for fourth-quarter revenue on Friday as sales of its blockbuster eye drug Eylea met drugmaker's preliminary estimates target. The shares gained 4% in premarket trading.
Eylea sales were $1.46 billion, including $123 million from the higher dose version of the drug, in line with the company's previously laid out targets in January.
Total revenue was $3.43 billion, beating analysts' estimates of $3.29 billion, according to LSEG data.
The company also said it has submitted its application to U.S. Food and Drug Administration to expand use of its eczema treatment Dupixent, in patients with a type of lung disease known as chronic obstructive pulmonary disease.
